Chetan Huded

Dr. Chetan Huded


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2022 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
CHChetan Huded
Chetan Huded
SASuzanne V. Arnold
Suzanne V. Arnold
ACAdnan K. Chhatriwalla
Adnan K. Chhatriwalla
JSJohn T. Saxon
John T. Saxon
SKSamir Kapadia
Samir Kapadia
DCDavid J. Cohen
David J. Cohen
Background: Rehospitalization is a common end point in clinical trials of structural heart interventions, but whether rehospitalization is clinically and prognostically relevant in these patients is uncertain. The aim of this study was to evaluate the risk of rehospitalization events after aortic valve replacement (AVR) and their association with mortality and health status. Methods: The study population included patients who underwent transcatheter or surgical AVR in the PARTNER I‚ II‚ and III trials (Placement of Aortic Transcatheter Valves). Health status was assessed with the Kansas City Cardiomyopathy Questionnaire-overall summary score. The primary analysis focused on heart failure hospitalization within 1 year after AVR and its association with mortality, poor outcome (death, Kansas City Cardiomyopathy Questionnaire-overall summary score <60 or decrease by ≥10), and health status at 1 year using adjusted models. Secondary analyses examined the prognostic associations of rehospitalization due to a composite of heart failure, valve-related, or procedure-related causes. Results: Among 3403 patients treated with AVR (2008 transcatheter AVR, 1395 surgical AVR), the 1-year incidence was 6.7% for heart failure hospitalization and 9.7% for rehospitalization due to a composite of heart failure, valve-related, or procedure-related causes. Heart failure hospitalization after AVR was associated with increased risk of 1-year mortality (hazard ratio, 3.97 [2.48 to 6.36]; P <0.001), poor outcome (OR, 2.76 [1.73 to 4.40]; P <0.001), and worse health status (Kansas City Cardiomyopathy Questionnaire-overall summary mean difference −9.8 points [−13.8 to −5.8]; P <0.001). Rehospitalization due to a composite of heart failure, valve-related, or procedure-related causes was similarly associated with increased 1-year mortality (hazard ratio, 4.64 [3.11 to 6.92]; P <0.001), poor outcome (OR, 2.06 [1.38 to 3.07]; P =0.0004), and worse health status (Kansas City Cardiomyopathy Questionnaire-overall summary mean difference −8.8 points [−11.8 to −5.7]; P <0.001). There was no effect modification by treatment type (transcatheter AVR versus surgical AVR) for these associations. Conclusions: Heart failure hospitalization and rehospitalization after AVR are associated with increased risk of mortality and worse 1-year health status. These findings confirm the clinical and prognostic relevance of rehospitalization end points for trials of AVR. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00530894.

20 September 2023 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
CHChetan Huded
Chetan Huded
SASuzanne V. Arnold
Suzanne V. Arnold
DCDavid J. Cohen
David J. Cohen
PMPratik Manandhar
Pratik Manandhar
SVSreekanth Vemulapalli
Sreekanth Vemulapalli
JSJohn A. Spertus
John A. Spertus

19 May 2023 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
AMAli O. Malik
Ali O. Malik
JSJohn T. Saxon
John T. Saxon
JSJohn A. Spertus
John A. Spertus
ASAdam Salisbury
Adam Salisbury
JGJames A. Grantham
James A. Grantham
CHChetan Huded
Chetan Huded
Intracoronary (IC) imaging for percutaneous coronary intervention (PCI) is associated with better patient outcomes and carries a class IIA guideline recommendation, but it remains rarely used. We sought to characterize hospital-level variability in IC imaging for PCI in the United States and to identify factors that may explain this variability. Patients who underwent PCI, with or without IC imaging, in the Nationwide Readmissions Database (2016-2020) were included. A regression model with a random effect for site was used to generate the median odds ratio (MOR) of IC imaging use for a patient at one site vs another, sequentially adjusting for procedural, patient, and hospital factors to examine the extent to which different factors account for this variability. The analytic cohort included 1,328,517 PCI procedures (patient mean age 65.8 years, 32.4% female, IC imaging used in 9.2%) at 1068 hospitals. The median hospital use of IC imaging increased from 2.7% (IQR, 0.6-7.7) in 2016 to 6.3% (IQR, 1.7-17.8) in 2020. In 2020, the MOR for IC imaging during PCI was 4.6 (IQR, 4.3-5.0), indicating a >4-fold difference in the odds of a patient undergoing IC imaging with PCI at one random hospital vs another. Adjusting for procedure, patient, and hospital factors did not meaningfully alter the MOR. The average US hospital uses IC imaging for <1 in 15 PCI procedures, with marked variability across hospitals. Strategies to increase and standardize the use of IC imaging are needed to improve the quality of PCI in the United States.

28 September 2022 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
AEAhmed Elkaryoni
Ahmed Elkaryoni
DCDavid J. Cohen
David J. Cohen
JLJohn J. Lopez
John J. Lopez
CHChetan Huded
Chetan Huded
KKKevin F. Kennedy
Kevin F. Kennedy
SASuzanne V. Arnold
Suzanne V. Arnold

11 November 2024 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
CHChetan Huded
Chetan Huded
ACAdnan K. Chhatriwalla
Adnan K. Chhatriwalla
MSMiloni A. Shah
Miloni A. Shah
SVSreekanth Vemulapalli
Sreekanth Vemulapalli
AKAndrzej Kosinski
Andrzej Kosinski
DCDavid J. Cohen
David J. Cohen

19 September 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RJRoopesh Sai Jakulla
Roopesh Sai Jakulla
SGSatya Preetham Gunta
Satya Preetham Gunta
CHChetan Huded
Chetan Huded
Severe aortic stenosis (AS) carries a poor prognosis with the onset of heart failure (HF) symptoms, and surgical or transcatheter aortic valve replacement (AVR) is its only definitive treatment. The management of AS has seen a paradigm shift with the adoption of transcatheter aortic valve replacement (TAVR), allowing for the treatment of AS in patients who would not otherwise be candidates for surgical AVR. Despite improving long-term survival after TAVR in recent years, residual HF symptoms and HF hospitalization are common and are associated with an increased mortality and a poor health status. This review article summarizes the incidence and risk factors for HF after AVR. Strategies for preventing and better managing HF after AVR are necessary to improve outcomes in this patient population. Extensive research is underway to assess whether earlier timing for AVR, prior to the development of severe symptomatic AS and associated extra-valvular cardiac damage, can improve post-AVR patient outcomes.